05/07/2019 SOURCE: www.fiercebiotech.com
Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and performing more sensitive screensConfo raises €30M A round to target hard-to-drug GPCRs
-
(0)
-
Bookmark
- Comments. (0)
05/07/2019 SOURCE: bioengineer.org
Reducing carbon emissions while improving health is economically attractive, study shows The price tag for cutting global emissions may seem expensive, until the human toll of deaths from air pollution and climate change are factored in, new research says. The price tag for cutting global emissions may seem expensive, until the human toll of deaths […]Global health benefits of climate action offset costs
-
(0)
-
Bookmark
- Comments. (0)
Advertisement
